EU watchdogs reverse course on Fampyra

Reversing an earlier decision, European regulators have recommended approving Acorda Therapeutics' drug Fampyra, which is designed to improve the walking ability of patients with multiple sclerosis. If approved, it will be marketed in Europe by Biogen Idec. Report